New iStopMM Research Released and More


The IMF’s Black Swan Research Initiative-Funded iStopMM Study Publishes Latest Outcomes The International Myeloma Foundation’s Black Swan Research Initiative® (BSRI) proudly showcased four oral and two poster abstracts from the iStopMM® (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, which took place from December 9-12, 2023. Also, this week in research news, the iStopMM study has had two articles published in Blood Cancer Journal. The first proposes developing a Bone Marrow Quality Index (BMQI). The second discusses how researchers used Next-Generation Flow cytometry to conduct an immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood. Learn more about the iStopMM Project at the button below.


Sarclisa (isatuximab-irfc) Meets Primary Endpoint in Phase III IMROZ Trial Sarclisa® (isatuximab-irfc), when added to the combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd), has been found to significantly reduce disease progression or the risk of death as compared to using VRd alone. This marks the first global phase III study to reveal positive outcomes when using an anti-CD38 therapy like Sarclisa in conjunction with VRd, specifically in patients who are not eligible for transplantation. Read the full article to learn more.


IMF Support Group Leaders Report Live During the 65th American Society of Hematology Annual Meeting and Exposition The IMF brought myeloma support group leaders and patients to the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, “the world’s most comprehensive hematology event of the year.” The IMF thanks these leaders for their care and commitment in sharing their experiences with the global myeloma community. We encourage you to visit the website and learn about these leaders’ unique perspectives


Save the Date: Top Myeloma Research at ASH 2023 from a Patient Perspective On Thursday, January 4, 2024, at 12:00 p.m. PST / 3:00 p.m. EST, IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie will discuss important Top Myeloma Research and Key Takeaways from the 2023 American Society of Hematology (ASH) Conference, along with a panel of patient advocates including Jessie Daw, PhD, and Michael Tuohy. Together, they will sift through the data of 1,000+ myeloma-related abstracts from the ASH conference and present key points in approachable terms for everyday decision-making.


Watch the Replay: IMF Chief Medical Officer Dr. Joseph Mikhael and the ASH Support Group Leaders Team LIVE at ASH 2023 IMF Chief Medical Officer Dr. Joseph Mikhael along with the ASH support group leader team went live to discuss key myeloma research takeaways from the 2023 American Society of Hematology Annual Meeting and Exposition. This Facebook Live Event took place on December 11th, live from ASH in San Diego. Visit the Facebook event page to view now.


Around the Web: Myeloma News To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. For this week, we encourage you to visit the results of this international survey in the Blood Cancer Journal about once-weekly Velcade (bortezomib) as the standard of care in multiple myeloma. Also in Blood Cancer Journal, read about “Real-world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database." As always, we invite you to visit the IMF Newsroom for the most recent myeloma news.

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

KTX-1001 (phase I trial – Now Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Fully Accrued)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Webinar Replays

Watch the Replay
IMF Patient and Family Webinar

Watch the Replay
M-Power Tampa

Watch the Replay
IMF Virtual Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

AbbVie, Bristol Myers Squibb, GSK, Janssen Oncology, Karyopharm Therapeutics,
Pfizer, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

We also thank individuals like you for your continued support!

Join the conversation at The International Myeloma Foundation

Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma

www.myeloma.org

This email was sent to by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Manage Subscriptions • Privacy Policy

View as web page